Amgen 6. Mai 2026 Biopharma Manufacturing Expands in the U.S.: Amgen, Lilly Double Down on Capacity and Next-Gen Production - BioPharm International
Amgen 4. Mai 2026 Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge? - 24/7 Wall St.
Amgen 4. Mai 2026 Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge? - Yahoo Finance
Amgen 2. Mai 2026 Biopharma bites: Novo rebrands Rybelsus as the Ozempic pill, and Amgen trims its pipeline - FirstWord Pharma
Amgen 1. Mai 2026 Repatha sales help Amgen overcome Prolia biosimilar hits in 1st quarter - Fierce Pharma
Amgen 1. Mai 2026 Amgen abandons candidates for cancer, Sjögren’s syndrome over weak ph. 2 data - Fierce Biotech
Amgen 29. Apr. 2026 Amgen, AstraZeneca join FDA effort harnessing cloud for real-time clinical trials - BioSpace
Amgen 28. Apr. 2026 FDA unveils plan for real-time review of clinical trial data, with AstraZeneca and Amgen already on board - Fierce Biotech
Amgen 28. Apr. 2026 FDA turns up heat on Amgen, proposing to rescind approval of Tavneos - Fierce Pharma
Amgen 24. Apr. 2026 Amgen’s Chief Technology Officer Dr David Reese to retire - European Pharmaceutical Review